Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies for treatment of ophthalmic disease
01 juin 2023 05h09 HE
|
Rentschler Biopharma SE
Rentschler Biopharma to conduct adeno-associated virus (AAV) process development work for manufacturing scale-up at their ATMP site in Stevenage, UKIkarovec is developing novel gene therapies to treat...
Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b
31 mai 2023 06h00 HE
|
Coave Therapeutics
CTx-PDE6b demonstrated clinically meaningful benefit in visual functions at the highest dose and exhibits a good safety profile Positive results from the study to date support preparations for a...
EHang Reports First Quarter 2023 Unaudited Financial Results
31 mai 2023 05h00 HE
|
EHang Holdings Limited
- Total Revenues Up 41.6% Quarter-over-Quarter- Continued High Quarterly Gross Margin of 60%+- EH216-S Type Certification’s Compliance Tests in Final Phase Completed More Than 90%- Notable Growth of...
Sania Therapeutics launches to advance novel medicines for neural circuit dysfunction
17 mai 2023 07h00 HE
|
Sania Therapeutics
Sania Therapeutics launches to advance novel medicines for neural circuit dysfunction Sania emerges from stealth mode and presents key proof-of-concept data at ASGCT 2023 ...
Coave Therapeutics to Participate in Upcoming Conferences
17 mai 2023 03h00 HE
|
Coave Therapeutics
Paris, France, May 17, 2023 - Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases,...
Locanabio Presents Preclinical Data from its Vectorized snRNA Exon Skipping Program for DMD and Cas13d Multi-targeting Program for C9orf72 ALS at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
16 mai 2023 06h00 HE
|
Locanabio, Inc.
LBIO-115 demonstrates robust exon 51 skipping resulting in high levels of dystrophin restoration in patient-derived muscle cells and an in vivo DMD disease model Cas13d Multi-targeting efficiently...
EHang Files Annual Report on Form 20-F for Fiscal Year 2022
27 avr. 2023 17h40 HE
|
EHang Holdings Limited
GUANGZHOU, China, April 28, 2023 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading autonomous aerial vehicle (“AAV”) technology platform...
EHang Reports Fourth Quarter and Fiscal Year 2022 Unaudited Financial Results
22 mars 2023 05h00 HE
|
EHang Holdings Limited
– EH216-S Type Certification (“TC”) Process Over 90% Completed– Continued High Quarterly and Annual Gross Margins of Over 65%– Post-TC Order Pipeline of EH216-S Exceeded 100 Units in China &...
Coave Therapeutics to Present at Upcoming Conferences
16 mars 2023 04h00 HE
|
Coave Therapeutics
Paris, France, March 16, 2023 - Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye...
EHang to Report Fourth Quarter and Fiscal Year 2022 Unaudited Financial Results on Wednesday, March 22, 2023
15 mars 2023 08h00 HE
|
EHang Holdings Limited
GUANGZHOU, China, March 15, 2023 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading autonomous aerial vehicle (“AAV”) technology platform...